Emory University: Carcinoma trials

The registry lists 23 Carcinoma studies with Emory University as lead sponsor. 4 are open to participants now and 8 have results posted.

Early Phase 1 2Phase 1 7Phase 2 9No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck CancerRecruitingNCT06914999Early Phase 1
• TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerRecruitingNCT06868433Phase 1
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationRecruitingNCT06662058Not applicable
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialRecruitingNCT06636734Phase 2
• Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedNCT04750473Phase 1Results posted
• Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell CarcinomaTerminatedNCT04495894Phase 2Results posted
• Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerCompletedNCT03800602Phase 2Results posted
• Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid CancerTerminatedNCT03506048Phase 2Results posted
• Pembrolizumab in Patients With Locally Advanced or Metastatic Skin CancerCompletedNCT02964559Phase 2Results posted
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
• Study of Everolimus (RAD001) in Combination With LenalidomideCompletedNCT01218555Phase 1Results posted
• Study of Induction Docetaxel, Cisplatin and 5-FluorouracilTerminatedNCT00400205Phase 2Results posted
• Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line TherapyWithdrawnNCT05315687Phase 2
• BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation TherapyCompletedNCT05250895Early Phase 1
• Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast CancerCompletedNCT05086731Not applicable
• Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnNCT03575234Phase 1
• Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation TherapyCompletedNCT03493789Phase 1
• VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1
• Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS TumorsActive, not recruitingNCT02574728Phase 2
• Ganetespib Window of Opportunity Study in Head and Neck CancersTerminatedNCT02334319Phase 1
• Video-Based Treatment Options for Basal Cell CarcinomaCompletedNCT02158650Not applicable
• Adjuvant Radiation for High Risk Bladder CancerTerminatedNCT01954173Not applicable
• Videoscopic Versus Open Inguinal Lymphadenectomy for CancerCompletedNCT01526486Not applicable